The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Acceleron Pharma’s (NASDAQ:XLRN) sotatercept for the treatment of patients with pulmonary arterial hypertension.
PRIME, akin to Breakthrough Therapy status in the
U.S., provides for more intensive guidance on development and
accelerated review of the market application.
Sotatercept is an investigational therapy that is not approved for any use in any country.
https://seekingalpha.com/news/3568197-ema-grants-prime-designation-to-accelerons-sotatercept
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.